Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News RADIOPHARM THERANOSTICS ADR RADX

Healthcare Biotechnology
Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical... see more

Recent & Breaking News (NDAQ:RADX)

    Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204

    GlobeNewswire 3 days ago

    Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

    GlobeNewswire October 20, 2025

    Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan

    GlobeNewswire October 20, 2025

    Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 'HEAT' Dose Escalation Clinical Trial

    GlobeNewswire October 1, 2025

    Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update

    GlobeNewswire July 29, 2025

    Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

    GlobeNewswire July 28, 2025

    Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

    GlobeNewswire July 22, 2025

    Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia

    GlobeNewswire June 24, 2025

    Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases

    GlobeNewswire June 11, 2025

    Radiopharm Theranostics Doses First Patient in Phase 1 'HEAT' Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors

    GlobeNewswire June 4, 2025

    Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake

    GlobeNewswire June 2, 2025

    ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

    GlobeNewswire May 19, 2025

    Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC)

    GlobeNewswire May 12, 2025

    Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference

    GlobeNewswire May 7, 2025

    New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution

    GlobeNewswire March 17, 2025

    New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases

    GlobeNewswire February 10, 2025

    Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement

    GlobeNewswire January 10, 2025

    Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia

    GlobeNewswire December 30, 2024

    RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

    GlobeNewswire December 20, 2024